EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Dupilumab Treatment Is Associated With Clinical Improvement and a Shift Toward a Health‐Associated Nasal Passage Microbiota in Diffuse Type 2 Chronic Rhinosinusitis

Fabio S Ryser iD, Tomas Demeter iD, Judith Bergada Pijuan iD, Srikanth Mairpady Shambat iD, Catrin Brühlmann, Tina Mauthe iD, Markus Hilty iD, Michael B Soyka iD, Urs C Steiner iD, Silvio D Brugger iD

Allergy · 2025

DOI: 10.1111/all.16600 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, 2025. Verfasst von Fabio S Ryser und 9 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School for Health Sciences, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Sinusitis, Antibodies, Monoclonal, Humanized, Rhinitis, Microbiota. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Urs C Steiner (UCS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nasal microbiota composition of patients with diffuse type 2 chronic rhinosinusitis with nasal polyps (CRSwNP) is altered compared to healthy individuals. Dupilumab, an anti‐IL‐4Rα‐mAb, modulates type 2 inflammation, but the effect on microbiota composition in CRSwNP is unknown. The aim of this study was to investigate longitudinal effects of dupilumab on the nasal passage and gastrointestinal microbiota in patients with diffuse type 2 CRSwNP.

Methods

Twenty‐seven patients with diffuse type 2 CRSwNP treated with dupilumab 300 mg subcutaneously every 2 weeks, 10 untreated patients with CRSwNP, and 11 healthy controls were included. Nasal and stool samples were collected at Days 0, 28, 90, and 180 posttreatment of the treated CRSwNP group and at Days 0 and 28 of untreated CRSwNP and healthy controls. The samples were analyzed using 16S rRNA gene amplicon sequencing (V3/V4).

Results

In CRSwNP patients, the most abundant genera in nasal passage microbiota were Corynebacterium and Staphylococcus . Cutibacterium and Lawsonella were less abundant in CRSwNP at baseline compared to healthy controls. Dupilumab treatment was associated with increased relative abundances in the nasal passage of genera such as Lawsonella, Corynebacterium , and Dolosigranulum . Microbial diversity of the gastrointestinal microbiota in CRSwNP at baseline was significantly higher than in healthy controls. There were no changes in gastrointestinal microbiota during dupilumab treatment.

Conclusion

Dupilumab treatment was associated with a shift in the nasal passage bacterial microbiota toward that of healthy controls, whereas the composition of gastrointestinal microbiota did not change. These findings suggest that nasal passage microbiota composition is influenced by the underlying inflammatory endotype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SinusitisAntibodies, Monoclonal, HumanizedRhinitisMicrobiotaHumansChronic DiseaseMaleFemaleMiddle AgedAdultNasal PolypsTreatment OutcomeAgedGastrointestinal MicrobiomeRhinosinusitis

Stichwörter der Autor:innen

CRSwNPbiologicalsdupilumabmicrobiomemicrobiotatype 2 inflammation

Substanzen

Antibodies, Monoclonal, Humanizeddupilumab

Autor:innen und Institutionen

  • Graduate School for Health Sciences, University of Bern, Bern, Switzerland.
  • Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Institute for Infectious Diseases, University of Bern, Bern, Switzerland.
  • Department of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

ORCID-Profile: Fabio S Ryser, Tomas Demeter, Judith Bergada Pijuan, Srikanth Mairpady Shambat, Tina Mauthe, Markus Hilty, Michael B Soyka, Urs C Steiner, Silvio D Brugger

Förderung

  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • Urs C Steiner (UCS)

Zitieren

APA

Ryser, F. S., Demeter, T., Pijuan, J. B., Shambat, S. M., Brühlmann, C., Mauthe, T., Hilty, M., Soyka, M. B., Steiner, U. C., & Brugger, S. D. (2025). Dupilumab Treatment Is Associated With Clinical Improvement and a Shift Toward a Health‐Associated Nasal Passage Microbiota in Diffuse Type 2 Chronic Rhinosinusitis. Allergy. https://doi.org/10.1111/all.16600

Vancouver

Ryser FS, Demeter T, Pijuan JB, Shambat SM, Brühlmann C, Mauthe T, et al. Dupilumab Treatment Is Associated With Clinical Improvement and a Shift Toward a Health‐Associated Nasal Passage Microbiota in Diffuse Type 2 Chronic Rhinosinusitis. Allergy. 2025. doi:10.1111/all.16600

BibTeX
@article{Ryser2025,
  author = {Ryser, Fabio S and Demeter, Tomas and Pijuan, Judith Bergada and Shambat, Srikanth Mairpady and Brühlmann, Catrin and Mauthe, Tina and Hilty, Markus and Soyka, Michael B and Steiner, Urs C and Brugger, Silvio D},
  title = {Dupilumab Treatment Is Associated With Clinical Improvement and a Shift Toward a Health‐Associated Nasal Passage Microbiota in Diffuse Type 2 Chronic Rhinosinusitis},
  journal = {Allergy},
  year = {2025},
  doi = {10.1111/all.16600}
}
Kostenlos starten →